AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 52 min read$MBRX

KLEMP WALTER V purchased 533,333 shares of MBRX

KLEMP WALTER V (CEO and President) purchased 533,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

Original reporting
SEC EDGAR · KLEMP WALTER V
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 3:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MBRX
Neutral
medium confidence
Mentioned
$MBRX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MBRXNeutralLow
01

Why it matters

The newest actionable detail is the CEO and President’s open-market purchase of 533,333 shares on Aug. 3, with holdings rising to 564,340 shares.

02

Market read

Traders may briefly reassess sentiment around MBRX due to insider buying, but the disclosure lacks fundamental drivers.

03

What to watch

No 10b5-1 plan is stated, but the filing also provides no rationale, no follow-on guidance, and no confirmation of intent beyond the transaction itself.

Relevance 3/10Novelty 4/10Timing: Form 4 filed Aug. 5 for a trade dated Aug. 3.

Background

The filing is an SEC Form 4 insider transaction for Moleculin Biotech, Inc. (MBRX).

Company-level read

Ticker impact

$MBRXNeutralMedium confidence
Context

Moleculin Biotech CEO and President KLEMP WALTER V bought 533,333 shares via an open-market Form 4 filed Aug. 5.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and may fade without follow-on fundamentals.

Evidence & confidence

The article discloses a large share count and that it was not under a pre-arranged 10b5-1 plan, but it lacks transaction price/value and does not include operational or financial catalysts.

Market effects

Sector

Minimal; this is company-specific insider activity with no disclosed sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buying without disclosed price/value can be routine liquidity or diversification rather than a strong forward-looking signal.

Key entities

  • issuer
    Moleculin Biotech, Inc.

    Subject of the Form 4 insider transaction disclosed in the article.

  • insider
    KLEMP WALTER V

    CEO and President who purchased 533,333 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MBRX insider trading history →

Related articles

AUG 31
$MBRXMedAI 8/10

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

Moleculin Biotech (MBRX) shares dropped 25% after interim trial data for Annamycin in AML patients showed no statistical significance, though remission rates were higher than standard chemotherapy. The MIRACLE trial continues with 67 of 90 patients enrolled. The company has $10.317M in cash, expected to last until Q3 2026. CEO Klemp called results encouraging but noted more data is needed.

stocktwits.com2 min
AUG 16
$MBRXMed

Moleculin's AML Trial Shows a Threefold Interim Remission Ad

Moleculin Biotech (Nasdaq: MBRX) reported preliminary unblinded interim efficacy from its MIRACLE pivotal AML trial on Aug. 14. In 45 patients, complete remission rates were 43% and 36% for Annamycin 190 and 230 mg/m² plus cytarabine versus 12% in control; composite CRc was 50% and 57% versus 29%. Company reported no cardiotoxicity to date and said cash was about $7.3M at June 30, 2026.

microcapobserver.com5 min
AUG 14
$MBRXMedAI 8/10

Moleculin Biotech, Inc. (MBRX): Results of Operations and Financial Condition

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML - MIRACLE trial ad

SEC EDGAR 8-K6 min
AUG 4
$MBRXMed

Moleculin reports promising preliminary phase II

Moleculin Biotech reported interim blinded Part A data from its MIRACLE Phase II/III trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory AML. In 62 evaluable patients, CR was 24% and CRc 37%. Among 30 prior venetoclax-failure patients, results were in a harder-to-treat group. Part A has 74/90 enrolled, completion expected by Sep 2026, unblinded results Dec 2026-Feb 2027.

indianpharmapost.com4 min
JUL 31
$MBRXHighAI 8/10

Moleculin Biotech Stock Is Sinking Friday: What's Going On? - Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech (NASDAQ:MBRX) priced a $9.3 million public stock offering at $0.75 per share, plus warrants, to fund clinical programs. Shares fell sharply on dilution concerns. In its MIRACLE trial, 62 evaluable patients showed 24% blinded complete remission and 37% composite complete remission. Recruitment reached 74 of 90 planned patients; full data unblinding expected Dec 2026 to Feb 2027.

benzinga.com6 min